SLC5A2 and chronic kidney disease: The recommended age to initiate CKD screening at age 55 years was somewhat sensitive to SGLT2 inhibitor costs and effectiveness in slowing CKD progression and reducing all-cause mortality, although our results were robust to variation in values for most model parameters examined.